<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005206A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005206</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>14019103</doc-number><date>20130905</date></document-id></application-reference><us-application-series-code>14</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>471</main-group><subgroup>04</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>471</main-group><subgroup>04</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>514256</main-classification><further-classification>546118</further-classification><further-classification>514303</further-classification><further-classification>544333</further-classification></classification-national><invention-title id="d0e43">INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>13938691</doc-number><date>20130710</date></document-id><parent-status>PENDING</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>14019103</doc-number></document-id></child-doc></relation></continuation><division><relation><parent-doc><document-id><country>US</country><doc-number>13552188</doc-number><date>20120718</date></document-id><parent-status>PENDING</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>13938691</doc-number></document-id></child-doc></relation></division><division><relation><parent-doc><document-id><country>US</country><doc-number>12852706</doc-number><date>20100809</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>8252812</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>13552188</doc-number></document-id></child-doc></relation></division><us-provisional-application><document-id><country>US</country><doc-number>61232603</doc-number><date>20090810</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>61305459</doc-number><date>20100217</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Samumed, LLC</orgname><address><city>San Diego</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Hood</last-name><first-name>John</first-name><address><city>San Diego</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Wallace</last-name><first-name>David Mark</first-name><address><city>San Diego</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Kumar KC</last-name><first-name>Sunil</first-name><address><city>San Diego</city><state>CA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>Samumed, LLC</orgname><role>02</role><address><city>San Diego</city><state>CA</state><country>US</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. Also provided are methods for treating Wnt-related disease states.</p></abstract></us-patent-application>